Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
The company is assessing the situation and simultaneously undertaking all the requisite action
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
The CAPSUL solution enables optimal process performance for production of premier quality PCL grades at competitive rates
Multi-ethnic innovation helps all complexions appear clearer and more uniform
Subscribe To Our Newsletter & Stay Updated
